Galmed Pharmaceuticals Fourth Quarter 2015 Conference Call and Webcast Scheduled for Tuesday, March 22nd, 2016

Mar 15, 2016, 08:30 ET from Galmed Pharmaceuticals Ltd.

TEL AVIV, Israel, March 15, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it will host a conference call and webcast on Tuesday, March 22nd, 2016 to discuss results for the period ended December 31, 2015 and to provide an update on current developments with respect to its clinical programs for Aramchol.

Conference Call & Webcast: Tuesday, March 22nd, 2016, 8:30 am Eastern Time / 5:30 am Pacific Time Participant Dial-In Numbers: Toll-Free:                                 +1-888-430-8691 Toll/International:                      +1-719-325-2491 Conference ID:                         7194562 Webcast:                       

Replay, available until April 5, 2016 Replay Dial-In Numbers: Toll-Free:                                 +1-877-870-5176 Toll/International:                      +1-858-384-5517 Passcode:                               7194562

About Galmed Pharmaceuticals Ltd.: Galmed is a clinical-stage biopharmaceutical company focused on the development of a novel, once-daily, oral therapy for the treatment of liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed believes that its product candidate, Aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, which is a chronic disease that Galmed believes constitutes a large unmet medical need. Galmed is currently conducting the ARREST Study, a multicenter, randomized, double blind, placebo-controlled Phase IIb clinical study designed to evaluate the efficacy and safety of Aramchol in subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. More information about the ARREST Study may be found on identifier: NCT02279524.

Forward-Looking Statements: This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to Galmed's objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that Galmed intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Galmed's most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission, or the SEC, on March 31, 2015, and in other filings that Galmed has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect Galmed's current views with respect to future events, and Galmed does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Logo -

SOURCE Galmed Pharmaceuticals Ltd.